Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma
The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...
Novartis
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006
Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...